News

Biocon announced that its long-standing partner, Duopharma Biotech Berhad (Duopharma Biotech) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year. As part of these contracts, Biocon`s subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia. The contracts comprise a three-year agreement valued at ~ MYR 155.27 million for human insulin, along with two 2-year agreements: ~ MYR 18 million for insulin glargine and ~ MYR 52.5 million for insulin aspart. In line with policies indicated in the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.

Biocon announced that the 48th Annual General Meeting(AGM) of the company will be held on 6 August 2026.

Biocon announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Biocon declined 63.45% to Rs 125.90 crore in the quarter ended March 2026 as against Rs 344.50 crore during the previous quarter ended March 2025. Sales rose 2.90% to Rs 4484.30 crore in the quarter ended March 2026 as against Rs 4358.10 crore during the previous quarter ended March 2025.For the full year,net profit declined 61.95% to Rs 385.60 crore in the year ended March 2026 as against Rs 1013.30 crore during the previous year ended March 2025. Sales rose 11.48% to Rs 16779.90 crore in the year ended March 2026 as against Rs 15052.20 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales4484.304358.10 3 16779.9015052.20 11 OPM %22.7524.74 -20.5921.04 - PBDT841.30902.70 -7 2807.503477.10 -19 PBT327.90466.40 -30 850.801790.10 -52 NP125.90344.50 -63 385.601013.30 -62 Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 7 May 2026.